Search Results
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
CMG901 (AZD0901, a first-in-class Claudin 18.2 ADC): Following its out-licensing to AstraZeneca for global development, multiple global Phase III clinical trials are being rapidly advanced. In February 2026, the first subject was dosed in this clinical trial, triggering a milestone payment. In
More news about: Keymed
Mar 26, 2026, 09:48 ET Bitmine Immersion Technologies (BMNR) kondigt de lancering aan van MAVAN (Made In America VAlidator Network), de eigen stakingoplossing van het bedrijf
Bitmine wordt ondersteund door een vooraanstaande groep institutionele investeerders, waaronder Cathie Wood van ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital en persoonlijke investeerder Thomas 'Tom' Lee ter ondersteuning van Bitmine's doel om 5% van alle ETH te verwerven.
More news about: Bitmine Immersion Technologies, Inc.
Mar 26, 2026, 09:44 ET Bitmine Immersion Technologies (BMNR) Umumkan Peluncuran MAVAN (Made In America VAlidator Network), Solusi Staking Miliknya
Bitmine tetap didukung oleh kelompok penting beranggotakan investor institusi seperti Cathie Wood dari ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital, dan investor pribadi Thomas "Tom" Lee guna mendukung tujuan Bitmine untuk mengakuisisi 5% ETH
More news about: Bitmine Immersion Technologies, Inc.
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
monotherapy for adults with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemoradiotherapy (CRT). With these approvals, sugemalimab has become one of only two anti-PD-(L)1 antibodies approved in both the EU and U.K. for Stage III NSCLC, positioning it as a comprehensive
More news about: CStone Pharmaceuticals
Mar 26, 2026, 09:26 ET Bernstein Litowitz Berger & Grossmann LLP and Kessler Topaz Meltzer & Check, LLP Announce Pendency of Class Action and Proposed Settlement of In re Mylan, N.V. Securities Litigation
SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION AND PROPOSED SETTLEMENT; (II) SETTLEMENT HEARING; AND (III) MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSESTO: All persons and entities who purchased or otherwise acquired the publicly traded
More news about: JND Legal Administration
Mar 26, 2026, 09:18 ET Einride Electrifies Regional Deliveries for Coop Grocery Stores in Sweden
[email protected] Merger Corp. IIIEric RosenfeldChief SPAC OfficerLegato Merger Corp. III[email protected] This
More news about: Einride
Mar 26, 2026, 09:16 ET Summary Notice of Pendency and Proposed Settlement Involving All Persons who Purchased or Otherwise Acquired GSX Securities Between June 6, 2019 and October 20, 2020, Inclusive
fair, reasonable, and adequate; (ii) dismiss the Action with prejudice as provided in the Stipulation and Agreement of Settlement, dated June 5, 2025; (iii) approve the proposed Plan of Allocation for distribution of the proceeds of the Settlement (the "Net Settlement Fund") to Settlement Class Members;
More news about: JND Legal Administration
Mar 26, 2026, 09:07 ET Bitmine Immersion Technologies (BMNR) 宣佈推出其專有質押解決方案 MAVAN（美國製造驗證者網絡）
3,142,643 枚以太幣 (ETH)，按每枚 2,148 美元計算，相當於 68 億美元Bitmine 持續獲得頂級機構投資者支持，包括 ARK 的 Cathie Wood、MOZAYYX、Founders Fund、Bill Miller III、Pantera、Kraken、DCG、Galaxy Digital 以及個人投資者 Thomas "Tom" Lee，攜手支持 Bitmine 收購 5% 以太幣的目標康州諾沃克2026年3月26日
More news about: Bitmine Immersion Technologies, Inc.
Mar 26, 2026, 09:01 ET A BitMine Immersion Technologies (BMNR) anuncia o lançamento da MAVAN (Made In America VAlidator Network), a solução proprietária de staking da empresa
A BitMine continua apoiada por um grupo de investidores institucionais de destaque, incluindo Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e o investidor pessoal Thomas "Tom" Lee, para apoiar a meta da BitMine de adquirir 5% do ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.
Mar 26, 2026, 09:00 ET SHINE and C-Ray Therapeutics Establish Strategic Partnership for Exclusive Distribution of Non-Carrier-Added Lu-177 in Mainland China
delivered 70+ projects spanning diagnostic and therapeutic programs, including 5 programs at IND or IND-enabling stage, 5 in clinical supply, and 2 in Phase III clinical trials. For more information, visit
More news about: SHINE Technologies, LLC
Mar 26, 2026, 08:56 ET Popular Docuseries "What Is Rich" Expands Nationwide with FOX SOUL Distribution Reaching 63 Million Households
leaders and changemakers including NBA star CJ McCollum, Fanbase creator Isaac Hayes III, Hollywood blockbuster producer Will Packer, Frenchy's Chicken chairman Percy Creuzot III, Purdue Board of Regents trustee Shawn Taylor, The Gathering Spot co-founder Ryan Wilson,
More news about: What Is Rich
Mar 26, 2026, 08:56 ET Bitmine Immersion Technologies (BMNR) anuncia el lanzamiento de MAVAN (Made In America VAlidator Network), la solución de staking exclusiva de la empresa
respaldo de un grupo de inversionistas institucionales de primer nivel, entre los que se encuentran Cathie Wood de ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital y el inversionista personal Thomas "Tom" Lee, con el fin de apoyar el objetivo de Bitmine de adquirir el 5 % de
More news about: Bitmine Immersion Technologies, Inc.
Mar 26, 2026, 08:53 ET CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
demonstrating its broad-spectrum therapeutic potential across multiple tumor types.Accelerated Global Phase III Development Plan: The company plans to initiate the first wave of Phase III global multi-regional clinical trials (MRCT) for CS2009 by the end of 2026, targeting indications including NSCLC,
More news about: CStone Pharmaceuticals
Mar 26, 2026, 08:53 ET C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China
delivered 70+ projects spanning diagnostic and therapeutic programs, including 5 programs at IND or IND-enabling stage, 5 in clinical supply, and 2 in Phase III clinical trials. For more information, visit www.c-raytherapeutics.com
More news about: C Ray Therapeutics
Mar 26, 2026, 08:50 ET Bitmine Immersion Technologies (BMNR) comunica il lancio di MAVAN (Made In America VALidator Network), la soluzione di staking proprietaria dell'azienda
continua a essere sostenuta da un gruppo di investitori istituzionali di prim'ordine tra cui Cathie Wood di ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e l'investitore privato Thomas "Tom" Lee a sostegno dell'obiettivo di Bitmine di acquisire il 5% di ETH
More news about: Bitmine Immersion Technologies, Inc.
Mar 26, 2026, 08:31 ET MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
related to vanoglipel (DA-1241) product development, (ii) $3.9 million in lower direct R&D expenses related to DA-1726 product development, and (iii) $0.2 million in lower direct other R&D costs. These decreases were partially offset by $0.1 million in higher indirect consulting expenses and a
More news about: MetaVia Inc.
Mar 26, 2026, 08:30 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
$790,000 is mainly comprised of (i) a $537,000 decrease in inventory impairments, (ii) a $228,000 decrease relating to bioinks and rhCollagen sales, and (iii) a $90,000 insurance reimbursement received in 2025.GAAP gross profit for the year ended December 31, 2025, was $1.5 million, compared to $1.1
More news about: CollPlant
Mar 26, 2026, 08:00 ET Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards
deal closure at the end of Q1 2026, Samsung Biologics continues to expand its manufacturing footprint. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.Samsung Biologics leverages
More news about: Samsung Biologics
Mar 26, 2026, 08:00 ET Contango Completes Merger with Dolly Varden
patented mining claims located in the Willow Mining District about 75 miles north of Anchorage, Alaska, from the underlying owner, Alaska Hardrock Inc., (iii) mineral rights to approximately 145,000 acres of State of Alaska mining claims, (iv) mineral rights to approximately 11,700 acres of State of Alaska
More news about: Contango Silver & Gold Inc.
Mar 26, 2026, 07:17 ET Natural Grocers® Invites Abilene, TX Community to Celebrate Grand Reopening on April 9, 2026
Grocers' Abilene, TX location. No rain checks. Limit one per customer, 18 years or older. Valid 4/9/2026 only. Void where prohibited by law.[iii] Prize wheel available at Natural Grocers' Abilene, TX location. No purchase necessary. Quantity limited to stock on hand; no rain checks. Valid 4/9/2026, 12
More news about: Natural Grocers by Vitamin Cottage, Inc.
Mar 26, 2026, 06:45 ET CMC Reports Second Quarter of Fiscal 2026 Results
allow: (i) comparison of our earnings to those of our competitors; (ii) a supplemental measure of our underlying business operational performance; and (iii) the assessment of period-to-period performance trends. Management uses non-GAAP financial measures to evaluate financial performance. We have not reconciled
More news about: CMC
Mar 26, 2026, 05:46 ET Yeahka Announces 2025 Annual Results
consumers through our one-stop payment services; (ii) enable merchants to better manage and drive business growth through our merchant solutions; and (iii) provide consumers with local lifestyle services of great value through our in-store e-commerce services.For more information, please visit
More news about: Yeahka
Mar 26, 2026, 02:01 ET Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children
population.1Marketing authorisations for PEDMARQSI® were based on safety and efficacy data from two open label, randomised Phase III trials: SIOPEL 6 (pivotal) and Clinical Oncology Group (COG) ACCL0431.2,3 Across these studies, sodium thiosulfate significantly reduced the
More news about: Norgine
Mar 26, 2026, 02:01 ET Norgine gibt die Swissmedic-Zulassung von PEDMARQSI® zur Vorbeugung von cisplatininduziertem Hörverlust bei Kindern bekannt
wurde.1Die Marktzulassung für PEDMARQSI® basierte auf Sicherheits- und Wirksamkeitsdaten aus zwei offenen, randomisierten Phase-III-Studien: SIOPEL 6 (zulassungsrelevant) und Clinical Oncology Group (COG) ACCL0431.2,3 In diesen Studien verringerte Natriumthiosulfat signifikant
More news about: Norgine
Mar 26, 2026, 02:01 ET Norgine annonce l'approbation par Swissmedic de PEDMARQSI® pour la prévention de la perte auditive induite par le cisplatine chez les enfants
patients.1Les autorisations de mise sur le marché du PEDMARQSI® ont été fondées sur les données de sécurité et d'efficacité de deux essais de phase III ouverts et randomisés : SIOPEL 6 (pivot) et Clinical Oncology Group (COG) ACCL0431.2,3 Dans l'ensemble de ces études, le thiosulfate de sodium
More news about: Norgine